drugset / Trial / NCT00295984

Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma

NCT00295984

Phase 2 Completed 24 enrolled National Cancer Institute (NCI)
Double-blindTreatment

Summary

RATIONALE: Nicotine may stimulate the immune system to kill Kaposi's sarcoma cells. PURPOSE: This phase II trial is studying the side effects and how well the nicotine skin patch works in treating patients with Kaposi's sarcoma.

Timeline

Start
2006-03
Primary completion
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Nicotine Unknown 7 mg Other

Indications